• 제목/요약/키워드: survival regression

검색결과 620건 처리시간 0.026초

Survival Time and Molecular Subtypes of Breast Cancer after Radiotherapy in Thailand

  • Kongsiang, Apichat;Tangvoraphonkchai, Vorachai;Jirapornkul, Chananya;Promthet, Supannee;Kamsa-ard, Siriporn;Suwanrungruang, Krittika
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권23호
    • /
    • pp.10505-10508
    • /
    • 2015
  • Background: Breast cancer is an important cause of death among women. One way of classifying different forms of breast cancer is by molecular features, usually in terms of the four subtypes: luminal A, luminal B, HER2-enriched, and triple negative. Objectives: This study aimed to investigate the association between molecular subtypes and survival among breast cancer patients treated with radiotherapy. Materials and Methods: A retrospective cohort study was conducted. The subjects were 272 breast cancer patients who had received treatment in the radiotherapy unit at Srinagarind Hospital, Thailand, between 1 January, 1999, and 31 May, 2009. The end of the study was 1 June, 2014. Overall survival was defined as the time elapsing between initial registration at the radiotherapy unit and death or the end of the study. Survival curves were estimated by the Kaplan-Meier method, and a multivariate analysis was performed using Cox's proportional hazard regression model. Results: The patient mean age was $47.5{\pm}10.4$ at the time of diagnosis. Of the 272 patients, 146 (53.7%) were classified as luminal A, 12 (4.4%) as luminal B, 30 (11.0%) as HER2-enriched, and 84 (30.9%) as triple negative. The overall survival rates at 1, 3 and 5 years were 87.1%, 68.4% and 59.2%, respectively. According to molecular subtypes, HER2-enriched patients had the lowest 5-year survival rate (30.0 %, 95%CI: 15.02-46.55). The median follow-up time was 8.37 years. In the Cox model analysis a higher risk of death was found for patients with HER2-enriched ($HR_{adj}=3.34$, 95%CI:1.96-5.67), triple negative ($HR_{adj}=2.17$, 95%CI: 1.44-3.27), and stage IIlB ($HR_{adj}=2.20$, 95%CI: 1.16-4.17) cancers. Conclusions: The worst survival rates were among patients classified as HER2-enriched, triple negative and at stage IIIB. Early detection and an advanced treatment modality are needed to help these patients.

Prognostic Value of Matrix Metalloproteinase 9 Expression in Breast Cancer Patients: A Meta-analysis

  • Song, Jian;Su, Hong;Zhou, Yang-Yang;Guo, Liang-Liang
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권3호
    • /
    • pp.1615-1621
    • /
    • 2013
  • Background: Matrix metalloproteinase 9 (MMP-9) is related to tumor invasion and metastasis. However, the role of MMP-9 expression in breast cancer survival remains controversial. The purpose of this study was to accomplish a more accurate estimation of the association between MMP-9 expression and survival results in breast cancer patients through meta-analysis. Methods: A meta-analysis of published studies investigating the effects of positive MMP-9 expression on both relapse free survival (RFS) and overall survival (OS) was performed. Relevant literature was confirmed by searching electronic databases including PubMed, Ovid, EMBASE and China National Knowledge Infrastructure (CNKI) before November 1, 2012. Individual hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled HRs with 95% CIs were used to evaluate the strength of the association between positive MMP-9 expression and survival results of breast cancer patients. Funnel plot and Egger's regression tests were used to evaluate publication bias. Heterogeneity and sensitivity analysis was also conducted. All the work was completed using STATA. Results: A total of 2,344 patients from 15 evaluative studies were finally included. Pooled HRs and 95% CIs suggested that MMP-9 overexpression had an unfavorable impact on both OS (HR: 1.70, 95% CI: 1.41-2.04) and RFS (HR: 1.54, 95% CI: 1.17-2.01) in breast cancer patients. There was no significant heterogeneity observed in the studies reported for OS (P=0.360, $I^2$=8.8%), but not RFS (P=0.002, $I^2$=67%). Publication bias was absent among the studies both in OS and RFS cases (t=-0.54, P=0.605 and t=1.71, P=0.131, respectively). Omission of any single study had little effect on the combined risk estimates on sensitivity analysis. Conclusion: The results of this meta-analysis suggest that positive MMP-9 expression confers a higher risk of relapse and a worse survival in patients with breast cancer. Larger prospective studies are now needed to evaluate the clinical utility of MMP-9 expression.

Effects of Antiretroviral Therapy on the Survival of Human Immunodeficiency Virus-positive Adult Patients in Andhra Pradesh, India: A Retrospective Cohort Study, 2007-2013

  • Bajpai, Ram;Chaturvedi, Himanshu;Jayaseelan, Lakshmanan;Harvey, Pauline;Seguy, Nicole;Chavan, Laxmikant;Raj, Pinnamaneni;Pandey, Arvind
    • Journal of Preventive Medicine and Public Health
    • /
    • 제49권6호
    • /
    • pp.394-405
    • /
    • 2016
  • Objectives: The survival outcomes of antiretroviral treatment (ART) programs have not been systematically evaluated at the state level in India. This retrospective study assessed the survival rates and factors associated with survival among adult human immunodeficiency virus (HIV)-infected patients in Andhra Pradesh, India. Methods: The present study used data from 139 679 HIV patients aged ${\geq}15$ years on ART who were registered from 2007 to 2011 and were followed up through December 2013. The primary end point was death of the patient. Mortality densities (per 1000 person-years) were calculated. Kaplan-Meier and Cox-regression models were used to estimate survival and explore the factors associated with survival. Results: The overall median follow-up time was 16.0 months (2.0 months for the deceased and 14.0 months for those lost to follow-up). Approximately 13.2% of those newly initiated on ART died during follow-up. Of those deaths, 56% occurred in the first three months. The crude mortality rate was 80.9 per 1000 person-years at risk. The CD4 count (adjusted hazard ratio [aHR],4.88; 95% confidence interval [CI], 4.36 to 5.46 for < $100cells/mm^3$ vs. > $350cells/mm^3$), functional status (aHR, 3.05; 95% CI, 2.82 to 3.30 for bedridden vs. normal), and body weight (aHR, 3.69; 95% CI, 3.42 to 3.97 for <45 kg vs. >60 kg) were strongly associated with the survival of HIV patients. Conclusions: The study findings revealed that high mortality was observed within the first three months of ART initiation. Patients with poor baseline clinical characteristics had a higher risk of mortality. Expanded testing and counseling should be encouraged, with the goal of ensuring early enrollment into the program followed by the initiation of ART in HIV-infected patients.

Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer

  • Fang, Hong;Lin, Rong-Yan;Sun, Ming-Xia;Wang, Qian;Zhao, Yu-Liang;Yu, Jing-Lin;Tian, Yan;Wang, Xiao-Yun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권24호
    • /
    • pp.10967-10970
    • /
    • 2015
  • Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I~II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of III degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy.

Adjuvant Chemotherapy in Patients with Node-Negative Non-Small Cell Lung Cancer with Satellite Pulmonary Nodules in the Same Lobe

  • Park, Jiyoun;Lee, Junghee;Jeon, Yeong Jeong;Shin, Sumin;Cho, Jong Ho;Kim, Hong-Kwan;Choi, Yong Soo;Kim, Jhingook;Zo, Jae Ill;Shim, Young Mog
    • Journal of Chest Surgery
    • /
    • 제55권1호
    • /
    • pp.10-19
    • /
    • 2022
  • Background: According to the eighth TNM (tumor-node-metastasis) staging system, the presence of separate tumor nodules in the same lobe is designated as a T3 descriptor. However, it remains unclear whether adjuvant chemotherapy confers survival advantages in this setting. Methods: We retrospectively identified 142 pathologic T3N0M0 patients with additional pulmonary nodules in the same lobe from a single-institutional database from 2004 to 2019. The main outcomes were overall survival and recurrence-free survival. Multivariable Cox regression was used to identify the benefit of adjuvant chemotherapy while adjusting for other variables. Results: Sixty-one patients received adjuvant chemotherapy (adjuvant group) and 81 patients did not receive adjuvant therapy after surgery (surgery-only group). There were no demonstrable differences between the 2 groups regarding hospital mortality and postoperative complications, indicating that treatment selection had not significantly occurred. However, the use of adjuvant chemotherapy was associated with improved 5-year overall survival (70% vs. 59%, p=0.006) and disease-free survival (60% vs. 46%, p=0.040). A multivariable Cox model demonstrated that adjuvant chemotherapy was associated with a survival advantage (adjusted hazard ratio, 0.54; p<0.001). In exploratory analyses of subgroups, the effect of adjuvant chemotherapy seemed to be insufficient in those with small main tumors (<4 cm). Conclusion: Adjuvant chemotherapy was associated with better survival in T3 cancers with an additional tumor nodule in the same lobe. However, the role of adjuvant chemotherapy in patient subgroups with small tumors or those without risk factors should be determined via large studies.

Association between High Diffusion-Weighted Imaging-Derived Functional Tumor Burden of Peritoneal Carcinomatosis and Overall Survival in Patients with Advanced Ovarian Carcinoma

  • He An;Jose AU Perucho;Keith WH Chiu;Edward S Hui;Mandy MY Chu;Siew Fei Ngu;Hextan YS Ngan;Elaine YP Lee
    • Korean Journal of Radiology
    • /
    • 제23권5호
    • /
    • pp.539-547
    • /
    • 2022
  • Objective: To investigate the association between functional tumor burden of peritoneal carcinomatosis (PC) derived from diffusion-weighted imaging (DWI) and overall survival in patients with advanced ovarian carcinoma (OC). Materials and Methods: This prospective study was approved by the local research ethics committee, and informed consent was obtained. Fifty patients (mean age ± standard deviation, 57 ± 12 years) with stage III-IV OC scheduled for primary or interval debulking surgery (IDS) were recruited between June 2016 and December 2021. DWI (b values: 0, 400, and 800 s/mm2) was acquired with a 16-channel phased-array torso coil. The functional PC burden on DWI was derived based on K-means clustering to discard fat, air, and normal tissue. A score similar to the surgical peritoneal cancer index was assigned to each abdominopelvic region, with additional scores assigned to the involvement of critical sites, denoted as the functional peritoneal cancer index (fPCI). The apparent diffusion coefficient (ADC) of the largest lesion was calculated. Patients were dichotomized by immediate surgical outcome into high- and low-risk groups (with and without residual disease, respectively) with subsequent survival analysis using the Kaplan-Meier curve and log-rank test. Multivariable Cox proportional hazards regression was used to evaluate the association between DWI-derived results and overall survival. Results: Fifteen (30.0%) patients underwent primary debulking surgery, and 35 (70.0%) patients received neoadjuvant chemotherapy followed by IDS. Complete tumor debulking was achieved in 32 patients. Patients with residual disease after debulking surgery had reduced overall survival (p = 0.043). The fPCI/ADC was negatively associated with overall survival when accounted for clinicopathological information with a hazard ratio of 1.254 for high fPCI/ADC (95% confidence interval, 1.007-1.560; p = 0.043). Conclusion: A high DWI-derived functional tumor burden was associated with decreased overall survival in patients with advanced OC.

The Prognostic Value of 18F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

  • Dan Shao;Qiang Gao;You Cheng;Dong-Yang Du;Si-Yun Wang;Shu-Xia Wang
    • Korean Journal of Radiology
    • /
    • 제22권3호
    • /
    • pp.425-434
    • /
    • 2021
  • Objective: To investigate the potential value of 18F-fluorodeoxyglucose (FDG) PET/CT in predicting the survival of patients with primary tracheal malignant tumors. Materials and Methods: An analysis of FDG PET/CT findings in 37 primary tracheal malignant tumor patients with a median follow-up period of 43.2 months (range, 10.8-143.2 months) was performed. Cox proportional hazards regression analyses were used to assess the associations between quantitative 18F-FDG PET/CT parameters, other clinic-pathological factors, and overall survival (OS). A risk prognosis model was established according to the independent prognostic factors identified on multivariate analysis. A survival curve determined by the Kaplan-Meier method was used to assess whether the prognosis prediction model could effectively stratify patients with different risks factors. Results: The median survival time of the 37 patients with tracheal tumors was 38.0 months, with a 95% confidence interval of 10.8 to 65.2 months. The 3-year, 5-year and 10-year survival rate were 54.1%, 43.2%, and 16.2%, respectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value, age, pathological type, extension categories, and lymph node stage were included in multivariate analyses. Multivariate analysis showed MTV (p = 0.011), TLG (p = 0.020), pathological type (p = 0.037), and extension categories (p = 0.038) were independent prognostic factors for OS. Additionally, assessment of the survival curve using the Kaplan-Meier method showed that our prognosis prediction model can effectively stratify patients with different risks factors (p < 0.001). Conclusion: This study shows that 18F-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with an MTV > 5.19, a TLG > 16.94 on PET/CT scans, squamous cell carcinoma, and non-E1 were more likely to have a reduced OS.

치유 절제술을 받은 위암 환자에서의 3년 무병생존이 5년 전체생존을 대치할 수 있는가? (Can 3-year Disease-free Survival be Substituted for 5-year Overall Survival in Curatively Resected Gastric Cancer?)

  • 권성준;김형주;김미경
    • Journal of Gastric Cancer
    • /
    • 제5권3호
    • /
    • pp.174-179
    • /
    • 2005
  • 배경: 대부분의 악성종양에 있어 그 치료성적을 평가하는 가장 유용한 방법으로 가장 많이 사용되는 매개변수는 전체 5년 생존율이다. 그러나 근치적 절제술이 시행된 위암환자에 있어 재발의 대부분은 수술 후 3년 이내에 일어나므로 3년 무병 생존이 5년 전체 생존의 의미를 대치할 수 있는가를 알아보고자 한다. 대상 및 방법: 근치적 위절제술을 받고 추적이 가능한 656예에서 생존 함수로 산출한 각각의 생존확률을 이용한 단순 회귀분석에서 3년 무병 생존이 5년 전체 생존을 대치할 수 있는지를 파악하였다. 결과: 추적 기간동안 175예에서 재발이 확인되었고, 재발시기별 누적빈도는 수술 후 1년이 81예(46%), 3년이 156예(89%), 5년이 170예(97%)였다. 3년 무병 생존확률과 5년 전체 생존확률 사이의 회귀 분석결과 상관성은 r=0.87, 설명력은 $R^2=0.76$, 회귀 방정식은 5년 전체 생존확률=0.18+($0.80{\times}3$년 무병 생존확률)을 나타냈다. 복막파종, 혈행성 전이, 국소 재발의 경우 상관성과 설명력은 각각 $r=0.89\;(R^2=0.80),\;r=0.88\;(R^2=0.78),\;r=0.86\;(R^2=0.73)$으로 모두 높은 상관관계가 있음을 나타냈다. 결론: 위암환자의 근치적 위절제술 후 3년 무병 생존 확률은 5년 전체 생존확률에 대한 높은 상관성 및 설명력을 보였다. 위암의 치료성적을 평가하는 방법으로 5년 전체 생존 대신에 3년 무병 생존을 이용한다면 기간을 단축(2년)하여 평가하고 결론을 얻고 또한 보고할 수 있는 이득이 있겠다.

  • PDF

임도 절토 비탈면의 안정과 식생활착에 미치는 환경인자의 영향 (Effects of Environmental Factors on the Stability and Vegetation Survival in Cutting Slope of Forest Roads)

  • 정원옥
    • 한국환경복원기술학회지
    • /
    • 제4권2호
    • /
    • pp.74-83
    • /
    • 2001
  • The purpose of this study was investigate to the influence of forest roads characteristics and environment factors on the soil erosion, stability and vegetation survival of cut slope in forest roads. The results obtained could be summarized as follows; 1. The correlated factors between slope erosion and variables in cut slope were altitude, convex, degree of slope, length of slope and soil depth. In the stepwise regression analysis, length of slope and soil hardness was a high significant and its regression equation was given by -89.6136 + 15.0667X14 + 16.6713X15($R^2$ = 0.6712). 2. The main factors influencing the stability of cut slope were significant in order of coverage, middle, convex, length of slope and north, and its discriminant equation was given by -1.019 + 0.064X22 - 0.808X8 - 0.622X24 + 0.742X11 - 0.172X14 - 0.545X6 ($R^2$ = 0.793). 3. The centroids value of discriminant function in the stability and unstability estimated to 1.244 and -1.348, respectively. The boundary value between two groups related to slope stability was -0.1038. The prediction rate of discriminant function for stability evaluation of was as high as 91.3%. 4. The dominant species of invasion vegetation on the cut slope consist with Carex humilis, Agropyron tsukushiense var. transiens, Calamagrostis arundinacea, Miscanthus sinensis var. purpurascens, and Ixeris dentata in survey area. The rate of vegetation invasion more increased by time passed. 5. The life form of invasion vegetation in cut slop showed to $H-D_1-R_{2,3}-e$ type of the hemicryptophyte of dormancy form, dissem inated widely by wind and water of dissminule type, moderate extent and narrowest extent of radicoid type, erect form of growth form. 6. The correlated factors between forest enviroment and coverage appeared north, passage years and middle position of slope at 5% level. The forest environment factors influencing the invasion plants in survey area were shown in order to altitude, passage years, rock(none), forest type(mixed) and stone amount. The regression equation was given by 17.5228 - 0.0911X3 + 3.6189X28 15.8493X22 19.8544X25 + 0.3558X26 ($R^2$ = 0.4026).

  • PDF

말기암환자에서 예후인자로서 혈청 Ferritin의 유용성 (Prognostic Value of Serum Ferritin in Terminally Ill Cancer Patients)

  • 이수희;최윤선;황인철;염창환;이준영
    • Journal of Hospice and Palliative Care
    • /
    • 제18권1호
    • /
    • pp.51-59
    • /
    • 2015
  • 목적: 말기암환자의 진료에 있어 여명을 예측하는 것은 매우 중요한 문제이다. 여러 악성 종양에서 혈청 ferritin이 증가되어 있고 높은 수치의 혈청 ferritin은 질병의 진행 및 나쁜 예후와 관련이 있다고 밝혀져 있으므로 본 연구에서는 말기암환자에서 ferritin과 생존기간과의 연관성을 알아보고 혈청 ferritin이 여명 예측 인자로 유용한지 검증하고자 하였다. 방법: 2012년 3월부터 2012년 6월까지 완화병동에 입원한 말기암환자 65명을 대상으로 혈청 ferritin을 포함한 기본적인 혈액검사를 시행하였고, 인구 통계학적 특성 및 임상증상 등을 조사하였다. 혈청 ferritin과 각 변수들간의 관련성을 파악하기 위해 Spearman's correlation analysis, Wilcoxon Rank Sum test 또는Kruskal-Wallis test등을 실시하였고 혈청 ferritin의 예후인자로서의 유용성을 평가하기 위해 다변수 콕스 비례위험 회귀분석(multivariable Cox's proportional hazard regression analysis)을 시행하였다. 결과: 상관 관계 분석 결과 ferritin은 생존기간과 유의한 음의 상관관계를 보였다. 단변량 분석에서 생존기간에 유의한 영향을 미치는 성별, ECOG 기능상태 지수, 크레아티닌, 백혈구 수치와 나이의 효과를 보정한 상태에서 혈청 ferritin은 말기암환자들의 생존기간과 통계적으로 유의한 관계를 나타내었다. 결론: 짧은 생존기간의 말기암환자에서도 혈청 ferritin은 독립적인 예후인자로 증명되었다. 기존의 여명 예측인자들과 더불어, 혈청 ferritin은 말기암환자들의 생존기간 예측에 도움을 줄 수 있을 것이라 생각한다.